Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196104 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
A Phase 3 study, sponsored by Mannkind Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT01196104: Clinical Trial Phase 3 study, sponsored by Mannkind Corporation.
NCT01196104 is a Phase 3 study that was terminated before completion, run by Mannkind Corporation. The registered enrollment target is 39 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196104, a Phase 3 study, was terminated before completion, sponsored by Mannkind Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with insulin glargine in subjects with type 2 diabetes.
Primary Outcome
Change from Baseline in glycated hemoglobin at Week 16
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Aspart
- DRUG Technosphere® Insulin Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Why NCT01196104 stopped before completion
NCT01196104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Insulin Glargine is the first listed.
NCT01196104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01196104 about?
NCT01196104 is a clinical study titled "Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler". This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with insulin glargine in subjects with type 2 diabetes.
What is the current status of trial NCT01196104?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2010-09. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01196104?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Aspart (DRUG), Technosphere® Insulin Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01196104?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01196104's enrollment target sits among peer trials
39 1898th of 2000 higher than 101 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia